4D Molecular Therapeutics - 4Front-2 over-enrolled with anticipated n>500; final randomization expected in Q3 2026

4D Molecular Therapeutics (Nasdaq: FDMT) has reported that its global Phase 3 clinical trial, 4FRONT-2, for 4D-150 in the treatment of wet age-related macular degeneration (wet AMD) has exceeded initial enrollment expectations. As of June 2026, the trial has randomized more than 500 patients, with final randomization anticipated in Q3 2026. This progress reflects strong engagement from investigators and patients across Europe and the Asia-Pacific regions, where site activation and patient screening have accelerated.

The 4FRONT-2 trial is designed to evaluate the safety and efficacy of 4D-150 in a global population of patients with wet AMD, including both treatment-naïve and recently diagnosed, treatment-experienced individuals. The trial follows an identical design to 4FRONT-1, the North American Phase 3 trial, which completed enrollment in February 2026 and randomization in March 2026. Topline data for 4FRONT-2 are expected in H2 2026, consistent with previous guidance.

The over-enrollment in 4FRONT-2 underscores the growing interest in 4D-150 as a potential durable treatment option for wet AMD. The therapy is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single intravitreal injection, potentially reducing the treatment burden associated with current therapies. Positive interim data from the Phase 1/2 PRISM trial have demonstrated consistent visual acuity maintenance, retinal anatomy control, and reduced treatment burden over up to 2 years of follow-up.

With the completion of 4FRONT-1 and the advancement of 4FRONT-2, 4DMT is on track to deliver topline data for both Phase 3 trials by mid-2027. The company’s cash position remains robust, with $458 million in cash, cash equivalents, and marketable securities as of March 31, 2026, supporting operations through the second half of 2028.